利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

42 条记录 (耗时 0.029 秒)

    Antibodies against human angiopoietin 2
    7.
    发明授权
    Antibodies against human angiopoietin 2 有权
    抗人血管生成素抗体2

    公开(公告)号：US09340609B2

    公开(公告)日：2016-05-17

    申请号：US13693085

    申请日：2012-12-04

    申请人： Hoffmann-La Roche Inc.

    发明人： Ulrich Brinkmann ,  Remko Albert Griep ,  Klaus Kaluza ,  Anita Kavlie ,  Christian Klein ,  Joerg Thomas Regula ,  Werner Scheuer

    IPC分类号： A61K39/00 ,  C07K16/22 ,  C12N15/85

    CPC分类号： C07K16/22 ,  A61K39/00 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/85

    摘要： The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises: (A) a heavy chain variable domain which comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2 and a CDR1 region of SEQ ID NO: 3; (B) a light chain variable domain which comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO: 5 and a CDR1 region of SEQ ID NO: 6. The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises: (A) a heavy chain variable domain which comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2 and a CDR1 region of SEQ ID NO: 3; (B) a light chain variable domain which comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO: 5 and a CDR1 region of SEQ ID NO: 6.

    摘要翻译： 本发明涉及一种治疗患者疾病或病症的方法，包括向需要这种治疗的患者施用特异性结合人血管生成素-2（ANG-2）的抗体，其中所述抗体包含：（ A）重链可变区，其包含SEQ ID NO：1的CDR3区，SEQ ID NO：2的CDR2区和SEQ ID NO：3的CDR1区; （B）轻链可变区，其包含SEQ ID NO：4的CDR3区，SEQ ID NO：5的CDR2区和SEQ ID NO：6的CDR1区。本发明还涉及一种预防 包括对需要这种预防性治疗的患者施用与人血管生成素-2（ANG-2）特异性结合的抗体，其中所述抗体包含：（A）重链可变结构域 其包含SEQ ID NO：1的CDR3区，SEQ ID NO：2的CDR2区和SEQ ID NO：3的CDR1区; （B）轻链可变区，其包含SEQ ID NO：4的CDR3区，SEQ ID NO：5的CDR2区和SEQ ID NO：6的CDR1区。